Recombinant Human 4-1BB Ligand/TNFSF9 protein (hFc Tag)

Species

Human

Purity

>95 %, SDS-PAGE

Tag

hFc Tag

Activity

EC50: 6-24 ng/mL

Cat no : Eg0079

---

Validation Data Gallery

• 

  Purity of Recombinant Human 4-1BB Ligand was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  Immobilized Human 4-1BB (Myc tag, His tag) at 0.5 μg/mL (100 μL/well) can bind Human 4-1BB Ligand (hFc tag) with a linear range of 6-24 ng/mL.

---

Product Information

• Purity: >95 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Immobilized Human 4-1BB (Myc tag, His tag) at 0.5 μg/mL (100 μL/well) can bind Human 4-1BB Ligand (hFc tag) with a linear range of 6-24 ng/mL.

• Expression: HEK293-derived Human 4-1BB Ligand protein Arg71-Glu254 (Accession# P41273) with a human IgG1 Fc tag at the N-terminus.
• GeneID: 8744
• Accession: P41273
• PredictedSize: 45.4 kDa
• SDS-PAGE: 45-50 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

TNFSF9 (Tumor necrosis factor ligand superfamily member 9) is also known as 4-1BBL (4-1BB ligand) or CD137L. TNFSF9 is a type 2 transmembrane glycoprotein receptor that is found on APCs (antigen presenting cells). TNFSF9 is expressed on activated T Lymphocytes. The TNFSF9/4-1BB complex with the help of T-cell receptor signals can trigger the increase in CD28− T cells and inhibit tumor growth. The interaction between 4-1BB and TNFSF9 provides costimulatory signals to T cells, which can be used to cancer immunotherapy.

References:

1.Jacob Bukczynski. et al. (2003). Eur J Immunol. 33(2): 446-54.
2.Adam T C Cheuk. et al. (2004). Cancer Gene Ther. 11(3): 215-26.
3.Chao Wang. et al. (2009). Immunol Rev. 229(1): 192-215.
4.Dass S Vinay. et al. (2012). Mol Cancer Ther. 11(5): 1062-1070.
5.Cariad Chester. et al. (2018). Blood. 131(1): 49-57.